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The translation of insights obtained in scholarly, academic 
research into practical clinical use is not a trivial issue and can-
not be left to itself to follow some sort of Darwinian selection 
principle (McClain, 2010). Rather, the development of a drug 
and new therapeutic approaches requires a concerted, well- 
organized effort. Yet, the process that takes ideas from basic 
research observations to medical practice is, unfortunately, long 
and inefficient (Fitzgerald, 2005). There are several discrete 
steps from the laboratory discovery to clinical application that 
include proof-of-concept studies in cellular and animal models, 
optimization of compounds or biologicals, evaluation of toxic-
ity, bioavailability, and many more. Experience has shown 
that it is mostly the interface between these different steps that 
does not always work smoothly, as people with different skills 
and cultural backgrounds pass on the projects, often over an 
entire decade. During the same period, a given pharmaceutical 
company is likely to experience a change in leadership several 
times. At the same time, drug discovery is subject to “fashions” that 
focus on a particular pathway or drug design strategy, or target 
specific classes of proteins. Thus, the latest discoveries in aca-
demia, the aforementioned career cycles, and the progress of 
a particular project are not necessarily in synchrony. As a 
result, the feedback to the community of cell biologists by 
the drug discovery experts may cause uncertainties, mistrust, 
and confusion.
From a systems cell biologist point of view, all biological 
processes occurring in a cell or in an organism contribute to 
cellular homeostasis and therefore can act as disease modulators. 
It follows that all processes are worth being interrogated with 
modulating agents—be they drugs or biologicals—at the exper-
imental level. Many cellular processes, such as the cell cycle, 
apoptosis, secretion, synaptic transmission, and epigenetic reg-
ulation are established pharmacological targets now, but have 
been unfashionable niches, neglected by the pharmaceutical 
industry for a long time. Likewise, there may be many other areas 
of cell biology, such as membrane biology, vesicular trafficking, 
intrinsically disordered proteins, chromosome segregation, and 
cell trans-differentiation that may garner mainstream attention 
by the industry soon.
There is hardly a cell biologist that works on a process 
or protein that has no “translational value.” On the contrary, 
rather than following some trendy area of recent successful 
medical application, pursuing a neglected area of cell biology 
and biochemistry with rigor and persistence, to the point of 
becoming a world expert, appears to promise a good chance of 
long-term translational impact. It is the depth with which a 
certain biological process is understood that empowers its transla-
tion. It is not the convention derived by the history of drug dis-
covery, such as if a target is considered druggable or not. For 
example, drugs targeting “allosteric” pockets of regulation, 
far away from the well-studied ortho-(proper) steric pockets 
are a current craze but were considered intractable until 
recently. Thus, every true expert in a particular process should 
have the peace of mind to explore as deep as necessary their 
process of interest, but then should be motivated to try “pharma-
cological interference” with tools of chemical biology or pro-
tein engineering. Being an expert on the biochemistry and 
biology of the process will allow the investigator to interpret 
and evaluate the consequence of the intervention wisely and 
to propose whether a particular “translational” avenue is worth 
exploring or not. This will eventually form the basis for the 
assays that, in partnership with the pharmaceutical/biotech 
industry, can lead to the discovery of new drugs and treat-
ments (Fig. 1).
All processes associated with cellular function are likely 
to contribute to disease. Particularly in the cancer field, 
most major therapeutic innovations have originated from 
the elucidation of basic molecular mechanisms by aca-
demic researchers. Recent breakthroughs in molecularly 
targeted drug discovery have made it clear that it is the 
depth with which a biological process is understood that 
empowers its translation. We propose that early, more 
strategic, support of cutting-edge academic research by 
industry may be more effective for translational purposes 
than the current model of a late selection of community-
evolved projects.
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and tested in preclinical models and partly in clinical trials 
(Hantschel, 2012; Hantschel et al., 2012; O’Hare et al., 2012). 
Additionally, a whole new set of reagents and methods was 
developed to monitor efficacy and selectivity of new agents, e.g., 
comprehensive screens for resistance mutations, selectivity pro-
filing using chemical proteomics, cocrystal structures, phospho-
proteomics and transcriptomics profiles, and many more (von 
Bubnoff et al., 2005; Bantscheff et al., 2007; Rix and Superti-
Furga, 2009). Likewise, basic insights into the biology of GIST, 
hypereosinophilic syndrome (HES), mastocytosis, and other 
diseases, its translation, and the rigid design of clinical trials 
expanded the spectrum of use of imatinib and its successors to 
other diseases (Heinrich et al., 2000).
The development of small-molecule kinase inhibitors 
for Bcr-Abl heralded a new era in drug discovery, showing 
for the first time that the pathological activation of a protein 
kinase can be specifically targeted, resulting in improved sur-
vival of patients (Druker, 2008). Additionally, we have seen 
steep progress in our understanding of Bcr-Abl biology over the 
past decade. We solved the puzzle of how the cognate cellular 
protein product of the proto-oncogene ABL1 is kept in a state of 
low kinase activity and have a better understanding of why 
Bcr-Abl is constitutively active (Hantschel and Superti-Furga, 
2004). Moreover, signaling pathways critical for the growth-
promoting and anti-apoptotic activity of Bcr-Abl were identified 
(Van Etten, 2007). Thus, it has been the detailed molecular 
understanding of the Abl kinases and their biology built from 
intense collaborative research of dozens of academic research 
groups that has been essential for this rapid progress. The les-
sons learned from Bcr-Abl served as a paradigm for the ensuing 
targeting of EGFR, VEGFR, ALK, BRAF and other kinases in 
solid tumors.
Still, many fundamental questions remain. The precise 
function of most of Bcr-Abl’s phosphorylation sites is not known 
and its molecular structure has been deciphered only in part. 
Basic questions concerning the regulation of Bcr-Abl transcrip-
tion, translation, and folding, including its critical interactions 
with chaperones, are only beginning to be revealed (Taipale 
et al., 2012). We only have a partial view of the Bcr-Abl signaling 
complex and signal transduction network, and regulation of its 
subcellular localization and nuclear–cytoplasmic partitioning is 
Bcr-Abl inhibitors illustrate the power of 
academia in drug discovery
Some of the principles that we just discussed are illustrated 
in the history of the targeted cancer therapeutic imatinib and 
its second-generation successors for the treatment of chronic 
myelogenous leukemia (CML), B cell acute lymphoblastic 
leukemia (B-ALL), gastrointestinal stromal tumors (GIST), and 
a few other diseases (Capdeville et al., 2002; Heinrich, 2010; 
Hantschel et al., 2012). Milestones in the imatinib discovery 
include the identification of Bcr-Abl fusion tyrosine kinase 
as the gene product of the Philadelphia chromosome and as 
causative lesion of CML, development of mouse models to 
study the disease and action of drugs, the use of phosphotyrosine-
specific antibodies to monitor the effects of small molecules 
on kinase activity, and the identification of an early lead com-
pound to possess potent inhibitory activity against Abl (Fig. 2; 
Buchdunger et al., 1996; Druker et al., 1996; Rowley, 2008). 
Finally, it was the persistence of a group of committed clini-
cians to convince Ciba-Geigy (now Novartis) to provide suffi-
cient amounts of imatinib to start a phase I and soon after 
a phase II clinical trial. Imatinib induced rapid and durable 
hematological and cytogenetic remission in most patients and 
has transformed CML from a dismal disease with poor survival 
to a chronic and well-manageable disease. Yet the first reports 
on clinical resistance to imatinib were published only a few 
months after the approval of imatinib for the treatment of CML 
(Fig. 2; Gorre et al., 2001). In the last 10 years, 100 mutations 
in the Bcr-Abl kinase domain have been identified that cause 
imatinib resistance. It was again the dedicated work of academic 
researchers and clinicians that uncovered additional molecular 
mechanisms of imatinib resistance in relapsed CML patients, 
including Bcr-Abl and Lyn overexpression, deletions and muta-
tions in Bcr-Abl “regulatory” domains, expression changes in 
drug transporters, and many more (O’Hare et al., 2006). All of 
these insights triggered and guided the rapid development and 
approval of second-generation Bcr-Abl inhibitors nilotinib and 
dasatinib (Shah et al., 2004; Weisberg et al., 2006). In parallel, 
a large number of drugs or drug-like molecules targeting mutated 
Bcr-Abl directly, newly identified allosteric sites on Bcr-Abl, 
proximal Bcr-Abl signaling nodes (Lyn, PP2A, STAT5, Jak2, 
Grb2), or pro-survival/anti-apoptotic pathways were developed 
Figure 1. Streamlining the drug discovery process. Schematic representation of the current way in which basic research makes its way to the pharmaceutical 
industry and our suggestions for improvements that would support and increase therapeutic innovation and its translation to the clinic.
 o
n
 N
ovem
ber 28, 2013
jcb.rupress.org
D
ow
nloaded from
 
Published November 12, 2012
573Cell biology: A key driver of therapeutic innovation • Hantschel and Superti-Furga
JAK2 kinase in patients with polycythemia vera (PV), essential 
thrombocythemia (ET), and primary myelofibrosis (PMF), and 
subsequently developed mouse models for this group of dis-
eases (Baxter et al., 2005; James et al., 2005; Kralovics et al., 
2005; Levine et al., 2005). This immediately triggered the start 
of JAK2 drug discovery programs in several companies and 
resulted in the development of JAK2 inhibitors and their clini-
cal evaluation in the following six years (Tefferi, 2012). De-
tailed work on the genetic basis of PV, ET, and PMF along with 
identification of several additional mutations by a number of 
different academic groups pointed out very early possible limi-
tations of JAK2 targeting in PV and ET (Kralovics, 2008), and 
this information will be critical to developing better therapies 
for these diseases.
For another hematological disease, diffuse large B cell lym-
phoma (DLBCL), classical work defined a distinct molecular 
subtype of DLBCL characterized by chronically activated B cell 
receptor signaling that depends on the activity of the Btk kinase 
(Alizadeh et al., 2000; Davis et al., 2010). Again, these insights 
from academic research put Btk in the limelight for the pharma-
ceutical industry. Several Btk kinase inhibitors are now in clini-
cal trials for both B cell lymphomas and chronic lymphocytic 
leukemia (CLL), as well as for autoimmune and chronic inflam-
matory disorders (Sheridan, 2012).
Although these examples are among the shining success 
stories of translational cancer research, they also illustrate the 
problems in the whole process and the decoupling of academia 
and industry. In all of them, the basic research community iden-
tified limitations in the use of a particular drugs, be it the iden-
tification of mechanisms of resistance or why a drug will not be 
effective in certain patients. Are there ways to better integrate 
the translation process across academia and industry?
still hazy. These many unknown molecular details may in part 
be the cause for the unclear mechanism of primary imatinib 
resistance. Also, the complex genetics and biology of the ad-
vanced disease stages of CML are not fully understood despite 
considerable efforts. Finally, CML is a prototypic stem cell dis-
ease, but the definition of CML stem cells and the factors gov-
erning their survival, self-renewal, and signaling are still heavily 
debated. Importantly, despite excellent improvements in overall 
survival of CML patients that was achieved over the past decade 
using tyrosine kinase inhibitors, CML is not curable. We believe 
that an even deeper understanding of Bcr-Abl biology and alter-
native “swim against the tide” approaches of targeting CML 
cells that go beyond simply generating new ATP-competitive 
inhibitors will be needed. These new approaches could include 
allosteric inhibitors, combinations of the growing arsenal of 
inhibitors, targeting kinases up- and downstream of Bcr-Abl, 
and targeting novel signaling nodes being identified in synthetic 
lethality screens and systems-type approaches.
Basic research has steered the 
development of many targeted cancer drugs
Until today, about a dozen small-molecule kinase inhibitors are 
FDA approved, all of which have become or are on their way to 
becoming blockbuster drugs for the producing pharmaceutical 
companies (Mullard, 2012). We describe a few examples that 
illustrate the outstanding importance of academic research in 
the development of these powerful drugs. A similar success 
story as Bcr-Abl inhibitors can be told on the development of 
the “first-in-class” JAK2 kinase inhibitor ruxolitinib that was 
approved for the treatment of myelofibrosis at the end of the last 
year (Mesa et al., 2012). In 2005, four different academic groups 
identified the activating point mutation V617F in the cytoplasmic 
Figure 2. Key events in the development of Bcr-Abl tyrosine kinase inhibitors. A timeline that highlights some of the important breakthroughs that led to 
the development of Bcr-Abl tyrosine kinase inhibitors. Ph+-ALL, Philadelphia chromosome–positive acute lymphoblastic leukemia.
 o
n
 N
ovem
ber 28, 2013
jcb.rupress.org
D
ow
nloaded from
 
Published November 12, 2012
JCB • VOLUME 199 • NUMBER 4 • 2012 574
References
Alizadeh, A.A., M.B. Eisen, R.E. Davis, C. Ma, I.S. Lossos, A. Rosenwald, 
J.C. Boldrick, H. Sabet, T. Tran, X. Yu, et al. 2000. Distinct types of 
diffuse large B-cell lymphoma identified by gene expression profiling. 
Nature. 403:503–511. http://dx.doi.org/10.1038/35000501
Arkin, M.R., and J.A. Wells. 2004. Small-molecule inhibitors of protein-protein 
interactions: progressing towards the dream. Nat. Rev. Drug Discov. 
3:301–317. http://dx.doi.org/10.1038/nrd1343
Bantscheff, M., D. Eberhard, Y. Abraham, S. Bastuck, M. Boesche, S. Hobson, T. 
Mathieson, J. Perrin, M. Raida, C. Rau, et al. 2007. Quantitative chemical 
proteomics reveals mechanisms of action of clinical ABL kinase inhibi-
tors. Nat. Biotechnol. 25:1035–1044. http://dx.doi.org/10.1038/nbt1328
Baxter, E.J., L.M. Scott, P.J. Campbell, C. East, N. Fourouclas, S. Swanton, 
G.S. Vassiliou, A.J. Bench, E.M. Boyd, N. Curtin, et al; Cancer Genome 
Project. 2005. Acquired mutation of the tyrosine kinase JAK2 in human 
myeloproliferative disorders. Lancet. 365:1054–1061.
Buchdunger, E., J. Zimmermann, H. Mett, T. Meyer, M. Müller, B.J. Druker, 
and N.B. Lydon. 1996. Inhibition of the Abl protein-tyrosine kinase in 
vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 
56:100–104.
Capdeville, R., E. Buchdunger, J. Zimmermann, and A. Matter. 2002. Glivec 
(STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. 
Rev. Drug Discov. 1:493–502. http://dx.doi.org/10.1038/nrd839
Cuatrecasas, P. 2006. Drug discovery in jeopardy. J. Clin. Invest. 116: 
2837–2842. http://dx.doi.org/10.1172/JCI29999
Davis, R.E., V.N. Ngo, G. Lenz, P. Tolar, R.M. Young, P.B. Romesser, H. 
Kohlhammer, L. Lamy, H. Zhao, Y. Yang, et al. 2010. Chronic active 
B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 
463:88–92. http://dx.doi.org/10.1038/nature08638
Druker, B.J. 2008. Translation of the Philadelphia chromosome into ther-
apy for CML. Blood. 112:4808–4817. http://dx.doi.org/10.1182/ 
blood-2008-07-077958
Druker, B.J., S. Tamura, E. Buchdunger, S. Ohno, G.M. Segal, S. Fanning, J. 
Zimmermann, and N.B. Lydon. 1996. Effects of a selective inhibitor of 
the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 
2:561–566. http://dx.doi.org/10.1038/nm0596-561
Filippakopoulos, P., J. Qi, S. Picaud, Y. Shen, W.B. Smith, O. Fedorov, E.M. 
Morse, T. Keates, T.T. Hickman, I. Felletar, et al. 2010. Selective inhibi-
tion of BET bromodomains. Nature. 468:1067–1073. http://dx.doi.org/ 
10.1038/nature09504
Fitzgerald, G.A. 2005. Opinion: anticipating change in drug development: the 
emerging era of translational medicine and therapeutics. Nat. Rev. Drug 
Discov. 4:815–818. http://dx.doi.org/10.1038/nrd1849
Gorre, M.E., M. Mohammed, K. Ellwood, N. Hsu, R. Paquette, P.N. Rao, and 
C.L. Sawyers. 2001. Clinical resistance to STI-571 cancer therapy caused 
by BCR-ABL gene mutation or amplification. Science. 293:876–880. 
http://dx.doi.org/10.1126/science.1062538
Hantschel, O. 2012. Allosteric BCR-ABL inhibitors in Philadelphia chromo-
some-positive acute lymphoblastic leukemia: novel opportunities for 
drug combinations to overcome resistance. Haematologica. 97:157–159. 
http://dx.doi.org/10.3324/haematol.2012.061812
Hantschel, O., and G. Superti-Furga. 2004. Regulation of the c-Abl and Bcr-Abl 
tyrosine kinases. Nat. Rev. Mol. Cell Biol. 5:33–44. http://dx.doi.org/ 
10.1038/nrm1280
Hantschel, O., F. Grebien, and G. Superti-Furga. 2012. The growing arsenal of 
ATP-competitive and allosteric inhibitors of BCR-ABL. Cancer Res. 
72:4890–4895. http://dx.doi.org/10.1158/0008-5472.CAN-12-1276
Heinrich, M.C. 2010. Imatinib treatment of metastatic GIST: don’t stop (be-
lieving). Lancet Oncol. 11:910–911. http://dx.doi.org/10.1016/S1470- 
2045(10)70225-4
Heinrich, M.C., D.J. Griffith, B.J. Druker, C.L. Wait, K.A. Ott, and A.J. Zigler. 
2000. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a 
selective tyrosine kinase inhibitor. Blood. 96:925–932.
James, C., V. Ugo, J.-P. Le Couédic, J. Staerk, F. Delhommeau, C. Lacout, 
L. Garçon, H. Raslova, R. Berger, A. Bennaceur-Griscelli, et al. 2005. 
A unique clonal JAK2 mutation leading to constitutive signalling 
causes polycythaemia vera. Nature. 434:1144–1148. http://dx.doi.org/ 
10.1038/nature03546
Kralovics, R. 2008. Genetic complexity of myeloproliferative neoplasms. 
Leukemia. 22:1841–1848. http://dx.doi.org/10.1038/leu.2008.233
Kralovics, R., F. Passamonti, A.S. Buser, S.S. Teo, R. Tiedt, J.R. Passweg, A. 
Tichelli, M. Cazzola, and R.C. Skoda. 2005. A gain-of-function mu-
tation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352: 
1779–1790. http://dx.doi.org/10.1056/NEJMoa051113
Levine, R.L., M. Wadleigh, J. Cools, B.L. Ebert, G. Wernig, B.J. Huntly, T.J. 
Boggon, I. Wlodarska, J.J. Clark, S. Moore, et al. 2005. Activating mutation 
Measures and suggestions
Our first suggestion is that cell biologists need to embrace 
systems-level approaches given that our understanding of most 
drugs’ true mechanism of action, i.e., at the systems level, is 
embarrassingly small. Chaperone inhibitors, proteasome inhibi-
tors, and drugs targeting epigenetic regulators all work through 
a semi-pleiotropic effect that we desperately should learn to 
assess. But ultimately, most therapeutic agents will affect mo-
lecular machines and processes likely to be already familiar to 
the community. Also, the list of protein–protein interactions 
targeted successfully is growing, raising the hopes that innu-
merable targeting possibilities will arise for the knowledgeable 
cell biologist (Arkin and Wells, 2004; Oltersdorf et al., 2005; 
Filippakopoulos et al., 2010). We speculate that to overcome 
one of the limiting factors in translational efforts, it is impor-
tant to lower the barriers for molecular cell biologists to attempt 
pharmacological (or biological entity-mediated) interference 
with the protein and process they best know and understand. 
Cultural resentments should be dismantled, making the cell 
biology community more comfortable in playing with chemis-
try. There is increasing evidence that academia is contributing 
to the discovery of first-in-class experimental chemical agents 
with new mechanisms (Cuatrecasas, 2006), often using pheno-
typic screens (Swinney and Anthony, 2011). The main area 
where the pharmaceutical industry indeed has tremendously 
valuable leadership that should be safeguarded is drug develop-
ment, in particular medicinal chemistry, ADME (absorption- 
distribution-metabolism-excretion), toxicology, and pharma-
ceutical formulation.
In addition to academic research laboratories valuing their 
research as inherently feasible for translation, industry should 
be less passive and opportunistic and also less responsive to 
general trends in their choice of project portfolios (see Fig. 1). 
Instead of waiting for innovation to trickle through the transla-
tional funnel until it hits the industry radar, strategic support of 
key laboratories showing leadership in the elucidation of key 
biological processes or protein families should be considered. 
Early, high-quality support with tools for chemical biology 
types of approaches would go a long way in both streamlining 
the value chain and diversifying the opportunities. The biotech 
industry, in the current financial environment short of cash, is ill 
positioned to cover enough of the interesting biology and be the 
sole broker between academia and pharma.
To summarize, for a general improvement of transla-
tional rates, we propose that academia and industry should 
enter into both more transparent and closer alliances than is 
currently the case. Instead of rushing “me-too” type of projects 
according to ever-changing fashions, trust should be placed in 
those academic laboratories with deep expertise in fundamen-
tally important areas of biology. Chances are good that through 
the early alliance, common campaigns will flourish that will 
couple modern molecular cell biology with the true translational 
impact it deserves.
Illustrations were provided by Neil Smith, www.neilsmithillustration.co.uk.
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